2Lim SL,Lim AK,Mumtaz M,et al.Prevalence,risk factors,and clinical features of thyroid-associated ophthalmopathy in multiethnic Malaysian patients with Graves' disease.Thyroid,2008;18(12):1297-1301.
3Kahaly G,Forester G,Hansen C.Glycosaminoglycans in thyroid eye disease.Thyroid,1998;8(5):429-432.
4Hatton MP,Rubin PA.The pathophysiology of thyroid-associated ophthalmopathy.Ophthalmol Clin North Am,2002;15(1):113-119.
5Bahn RS,Heufelder AE.Pathogenesis of Graves' ophthalmopathy.N Engl J Med,1993;329(20):1468-1475.
6Pilarska K,Kulig G,Krzystolik Z.The assessment of urinary glycosaminoglycans (GAG) excretion during therapy of patients with progressive Graves' ophthalmopathy.Pol Arch Med Wewn,2001;105(2):39-44.
7Kahaly G,Forster G,Hansen C.Glycosaminoglycans in thyroid eye disease.Thyroid,1998;(8):429-432.
8Daroszewski J,Rybka J,Gamian A.Glycosaminoglycans in the pathogenesis and diagnostics of Graves's ophthalmopathy.Postepy Hig Med Dosw,2006;60(3):370-378.
9Bahn RS,Gorman CA,Woloschak GE,et al.Human retroocular fibroblasts in vitro:a model for the study of Graves' ophthalmopathy.J Clin Endocrinol Metab,1987; 65(4):665-670.
10Bartalena L,Wiersinga WM,Pinchera A.Graves' ophthalmopathy:state of the art and perspectives.J Endocrinol Invest,2004;27(3):295-301.
